Previous Close | 0.0500 |
Open | 0.0500 |
Bid | 0.0400 x N/A |
Ask | 0.0500 x N/A |
Day's Range | 0.0500 - 0.0500 |
52 Week Range | 0.0400 - 0.2500 |
Volume | |
Avg. Volume | 139,099 |
Market Cap | 9.537M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0310 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Calgary, AB – TheNewswire - June 24, 2022 – Universal Ibogaine Inc. (TSXV:IBO), (OTC:IBOGF) and (FSE:JC4) (“UI” or the “Company”) a life sciences company with a mission to transform addiction treat...
Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) ("UI" or the "Company") a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model is pleased to announce that UI Co-Founder Dr Alberto Sola will present at the May 27 to 29 event: From Research to Reality: Global Summit on Psychedelic Assisted Therapies and Medicine which will be held in Toronto, Canada from May 27 to 29, 2022.
Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) ("UI" or the "Company") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has retained Mr. Shayne Nyquvest in a consulting role as Capital Markets Advisor.